Roivant Sciences ROIV

NASDAQ ROIV

$41.68 +0.20 (+0.48%)

As of: Sep 9, 2026 · 2:11 PM EDT

Roivant Sciences (ROIV) Operating Margin Growth (5y) (2025 - 2026)

Analysis

Roivant Sciences (ROIV) Operating Margin Growth (5y) (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	210.98 Bn	196.99 Bn	7.24 Bn
2	Gilead Sciences	181.24 Bn	178.06 Bn	6.22 Bn
3	Vertex Pharmaceuticals	132.38 Bn	124.53 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	82.97 Bn	74.97 Bn	3.93 Bn
5	Argenx Se	61.59 Bn	56.41 Bn	1.37 Bn
6	Moderna	54.80 Bn	49.67 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	34.09 Bn	30.78 Bn	992.69 Mn
8	Biogen	31.34 Bn	30.05 Bn	1.96 Bn
9	Roivant Sciences	30.11 Bn	30.11 Bn	1.16 Mn
10	Insmed	28.19 Bn	27.03 Bn	358.27 Mn

Historic Data

Historic Data

Download Data

Date	Value
Jun 30, 2026	-2.34 Mn
Dec 31, 2025	-1.17 Mn
Sep 30, 2025	-766,060.00
Jun 30, 2025	-586,780.00

Roivant Sciences

NASDAQ: ROIV

$41.68 ▲ +0.20 (+0.48%)

Sep 9, 2026 · 2:11 PM EDT